INVO Fertility (NASDAQ:IVF) Posts Quarterly Earnings Results

INVO Fertility (NASDAQ:IVF) released its earnings results on Tuesday. The company reported $472.78 earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $1.60 million for the quarter.

INVO Fertility Price Performance

INVO Fertility stock opened at $1.47 on Tuesday. INVO Fertility has a 12-month low of $1.38 and a 12-month high of $202.80. The company has a market capitalization of $2.37 million, a price-to-earnings ratio of 0.00 and a beta of 2.31. The firm’s fifty day moving average price is $2.09 and its 200 day moving average price is $5.20.

Wall Street Analyst Weigh In

IVF has been the topic of a number of research reports. Wall Street Zen upgraded shares of INVO Fertility from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Maxim Group set a $20.00 price objective on shares of INVO Fertility in a research report on Tuesday, February 10th. Finally, Weiss Ratings raised shares of INVO Fertility from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Institutional Investors Weigh In On INVO Fertility

An institutional investor recently bought a new position in INVO Fertility stock. Citadel Advisors LLC bought a new position in INVO Fertility, Inc (NASDAQ:IVF) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned about 1.19% of INVO Fertility as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 12.02% of the company’s stock.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.